19 VESTRY STREET, NEW YORK, NY
MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER ENDED MARCH 31, 2026 (All amounts expressed in Canadian dollars, unless otherwise stated)
Management's Discussion and Analysis for the First Quarter Ended December 31, 2025
Registration Statement on Form F-3
ANNOUNCES CLOSING OF US$175 MILLION PUBLIC OFFERING
ANNOUNCES PRICING OF UPSIZED US$175 MILLION PUBLIC OFFERING OF COMMON STOCK
ANNOUNCES LAUNCH OF US$100 MILLION PUBLIC OFFERING
And Piper Sandler & Co. Terminate Equity Distribution Agreement
Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)
Annual Report of Foreign Private Issuer Pursuant to Section 13(a) or 15(d)
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(3)
Notice of Exempt Offering of Securities
No filings found
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Free Writing Prospectus
Appointment of Agent for Service of Process by Foreign Banks and Foreign Insurance Companies
Correspondence
Submission Upload